Industry News (Therapy)
Expanded Access Program for Viramune Initiated
Published in AIDS Weekly, February 19th, 1996
Viramune is an investigational drug that belongs to a new class of anti-retroviral compounds called non-nucleoside reverse transcriptase inhibitors. The target date for commencement of the expanded access program is in March 1996, after finalizing the protocol with the U.S. Food and Drug Administration (FDA).
The major criteria for inclusion in the program include: male or female patients over 13 years of age with HIV-1 infection and a CD4+ cell count at or below 50. ...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1996-02-19)
More Articles from AIDS Weekly
- Conference Coverage (Retrovirus)
Radical Change in AIDS Therapy - Conference Coverage (Retrovirus)
AIDS Vaccine Data Called "Unpleasant, Unpalatable" - Conference Coverage (Retrovirus)
Cell Genesys Gene Therapy Safe in Early Trial - Conference Coverage (Retrovirus)
Chemokines Can Both Suppress and Activate HIV - Conference Coverage (Retrovirus)
HIV Infected Subjects Dampen Hopes for Chiron, Genentech Vaccines - Conference Coverage (Retrovirus)
New Drug Clinically Active Against Both HIV and CMV - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
